Europe grants Patent for GeneQuine’s Lead Product [ 07 Apr 2020 ]
The European Patent Office grants Patent covering GeneQuine’s lead gene therapy candidate GQ-303 for treatment of osteoarthritis.
GeneQuine Adds World Renowned Osteoarthritis Key Opinion Leader Prof. Yves Henrotin to Advisory Board [ 13 Jan 2020 ]
GeneQuine Biotherapeutics, a biotech company developing gene therapy for osteoarthritis and other musculoskeletal disorders, is pleased to name the internationally recognized osteoarthritis key opinion leader Prof. Yves Henrotin as a new member of the advisory board.
European Patent Office Issues Intention to Grant Notice for Patent Covering GeneQuine’s Product Candidate GQ-303 [ 26 Nov 2019 ]
The European Patent Office issued an intention to grant notice for patent application no. 14 708 933.8 – 1120, covering GeneQuine’s lead gene therapy candidate GQ-303 for treatment of osteoarthritis.
Flexion Therapeutics’ FX201, a Gene Therapy Candidate for the Treatment of Osteoarthritis, Receives IND Clearance by FDA Triggering Milestone Payment from Flexion to GeneQuine Biotherapeutics [ 12 Nov 2019 ]
Flexion’s IND application for FX201, which has the potential to provide long-term symptomatic relief and modify disease progression in knee osteoarthritis, was cleared by the FDA triggering a milestone payment from Flexion to GeneQuine. A Phase 1 single ascending dose study with FX201 has been initiated by Flexion and the first patient is expected to be treated by the end of 2019. GeneQuine believes that the FX201 IND approval will facilitate the transition of GeneQuine’s independent lead program GQ-303 from preclinical to clinical stage expected in 2021, as GQ-303 is also a gene therapy candidate for the treatment of osteoarthritis based on the same gene therapy vector technology.
US Patent Covering Gene Therapy Drug Candidates for Treatment of Osteoarthritis Issued [ 07 Jun 2019 ]
The U.S. Patent and Trademark Office (USPTO) grants a patent for FX201 (GeneQuine’s former human drug candidate GQ-203, acquired by Flexion Therapeutics, Inc.) and veterinary analogs for treatment of osteoarthritis.
GeneQuine opens up a new research and development site in the greater Berlin area (state of Brandenburg, Germany) and receives a local government grant (GRW program) to support establishing the site.
GeneQuine on Expert Panel Discussion at Merck’s Advance Biotech Grant Program Award Ceremony, 31 January 2019, Darmstadt [ 29 Jan 2019 ]
As a previous winner of Mercks’s European Emerging Biotech Grant Program, GeneQuine’s CEO Kilian Guse will hold an introductory speech on how the grant accelerated GeneQuine's development of a novel gene therapy platform and supported the lead program in osteoarthritis.
Preclinical Results from Osteoarthritis Gene Therapy Studies Published by GeneQuine and Collaborators in Leading Arthritis Journal [ 14 Sep 2018 ]
A scientific paper reporting preclinical small and large animal data of the gene therapy approach for osteoarthritis developed by GeneQuine and Baylor College of Medicine was published in “Arthritis & Rheumatology”, a leading peer-reviewed journal in the field. The data suggest symptomatic and disease-modifying efficacy in osteoarthritis treatment.
Positive Data on Osteoarthritis Gene Therapy Generated by GeneQuine and Collaborators Presented at OARSI World Congress (26 – 29 April 2018, Liverpool) [ 20 Apr 2018 ]
The osteoarthritis gene therapy approach developed by Baylor College of Medicine and GeneQuine demonstrated symptomatic and disease-modifying efficacy in small and large osteoarthritis animal models.
GeneQuine to attend Biopartnering and Investment Conference BioTrinity in London April 23 – 25, 2018 [ 12 Apr 2018 ]
Meet GeneQuine’s CEO Kilian Guse at BioTrinity to discuss partnering and investment options.
GeneQuine's CEO was interviewed by Animal Pharm regarding the company's partnering strategy for osteoarthritis product candidates for horses and dogs.
GeneQuine Biotherapeutics’ Gene Therapy Program for Treatment of Knee Osteoarthritis Acquired by Flexion Therapeutics [ 14 Dec 2017 ]
Knee osteoarthritis program developed by Hamburg-based gene therapy specialist GeneQuine Biotherapeutics acquired by Flexion Therapeutics for up to $64 million. Program holds potential to provide long-lasting pain relief and disease modification, and pending positive pre-clinical results is anticipated to enter clinical trials in 2019.
GeneQuine and Panion Eyeing License Deal for Osteoarthritis Gene Therapy in Horses and Dogs [ 18 May 2017 ]
GeneQuine Biotherapeutics GmbH and Panion Animal Health AB have signed a Letter of Intent to facilitate discussions regarding a potential license for GeneQuine’s gene therapy technology to treat osteoarthritis in horses and dogs.
Sponsor Fee Waiver for FY 2017 Granted by FDA [ 03 Apr 2017 ]
FDA grants GeneQuine Biotherapeutics a sponsor fee waiver under the significant barrier to innovation provision of ADUFA (Animal Drug User Fee Act) for FY 2017
Turkey Grants Patent for GeneQuine’s Lead Products [ 02 Mar 2017 ]
Following Europe and China, the Turkish Patent Office grants the Patent for GeneQuine’s Lead Products.
Chinese Patent Office grants Patent for GeneQuine’s Lead Products.
The Emerging Biotech Grant Program, sponsored by Merck KGaA, helps upcoming biotech companies with financial and research support.
GeneQuine to Present at Cell Therapy Manufacturing & Gene Therapy Congress (November 29 - 30, 2016, Amsterdam) [ 23 Nov 2016 ]
GeneQuine's CEO Kilian Guse will present at the Cell Therapy Manufacturing & Gene Therapy Congress on November 29. Dr. Guse will showcase GeneQuine's novel gene therapy platform and highlight data from the lead osteoarthritis development program.
Labiotech Refresh is Europe's most refreshing Biotech conference, showcasing the industry’s trends in a dynamic and modern way.
BioPharm Insight publishes article on GeneQuine [ 10 Nov 2016 ]
GeneQuine's CEO Kilian Guse was interviewed by BioPharm regarding company's technology platform, pipeline and upcoming financing.
GeneQuine to Present at Bio Europe Partnering Conference (November 7-9, 2016, Cologne, Germany) [ 03 Nov 2016 ]
GeneQuine's CEO Kilian Guse will present at the Bio Europe Partnering Conference on Nov 9 at 9:30 AM (conference room A, level 0). Dr. Guse will introduce GeneQuine's novel gene therapy platform and highlight data from the lead osteoarthritis development program.
GeneQuine’s CEO Kilian Guse to Discuss Advances in Cell and Gene Therapy in Panel Discussion at the Sachs 16th Annual Biotech in Europe Forum, 27 - 28 September 2016, Basel [ 21 Sep 2016 ]
Kilian Guse will discuss advances in cell and gene therapies with other leaders in the field and present GeneQuine’s development programs.
GeneQuine to Attend Phacilitate Cell & Gene Therapy Europe Conference, 21-22 September, Berlin [ 13 Sep 2016 ]
GeneQuine Biotherapeutics, a company focused on the development of a novel gene therapy platform, will attend the Phacilitate Cell & Gene Therapy Europe conference held in Berlin.
|transkript publishes article on GeneQuine [ 02 Jun 2016 ]
GeneQuine was featured in |transkript, a leading life science magazine in the German-speaking region.
GeneQuine’s CEO Kilian Guse to participate in Gene Therapy Panel Discussion at Labiotech Refresh Conference (May 24, 2016, Berlin) [ 18 May 2016 ]
Kilian Guse will discuss the current state and the future of gene therapy at Labiotech Refresh Conference on a panel with other leaders in the field.
GeneQuine’s CEO Dr. Kilian Guse to Present at 12min.MED-Life Science (March 17, 2016, University Medical Center Hamburg-Eppendorf) [ 07 Mar 2016 ]
GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at 12min.MED-Life Science.
Meet us at the European Animal Health Investment Forum 2016 (February 10 - 11, 2016, London) [ 27 Jan 2016 ]
GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will attend the European Animal Health Investment Forum held in London.
Sponsor Fee Waiver for FY 2016 Granted by FDA [ 18 Jan 2016 ]
FDA grants GeneQuine Biotherapeutics a sponsor fee waiver under the significant barrier to innovation provision of ADUFA (Animal Drug User Fee Act) for FY 2016
GeneQuine Biotherapeutics to Present at Arabian Tech Tour 2015 (November 2, 2015 in Jeddah, Saudi Arabia) [ 14 Oct 2015 ]
GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at Arabian Tech Tour 2015 in Jeddah, Saudi Arabia. The Arabian Tech Tour offers a platform for high-tech companies to present their business to an invited delegation of international and local investors as well as regional high profile stakeholders.
GeneQuine Biotherapeutics to Present at 2015 KC Animal Health Investment Forum (September 1, 2015, Kansas City) [ 18 Aug 2015 ]
GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at 2015 KC Animal Health Investment Forum. The KC Animal Health Investment Forum provides a unique opportunity for companies in the animal health sector to present their vision and business plan to potential investors and development Partners.
GeneQuine featured on LaBiotech Tour [ 29 Jun 2015 ]
Within their North German Tour LaBiotech has visited GeneQuine in Hamburg.
Animal Pharm publishes article on GeneQuine [ 23 Jun 2015 ]
GeneQuine was featured in Animal Pharm, a leading news website for the animal health sector.
GeneQuine’s CEO Interviewed at VetHealth Global 2015 Conference [ 19 Jun 2015 ]
Dr. Kilian Guse was interviewed by Canadian TV on June 8th about the VetHealth Global 2015 Conference and its importance in the Animal Health Industry.
GeneQuine Biotherapeutics to Present at VetHealth Global 2015 Conference (June 8-10, 2015, Prince Edward Island, Canada) [ 04 Jun 2015 ]
GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at VetHealth Global 2015, the International Animal Health & Nutrition Business Conference
GeneQuine Biotherapeutics Granted Sponsor Fee Waiver by FDA [ 28 May 2015 ]
FDA grants GeneQuine Biotherapeutics a sponsor fee waiver under the significant barrier to innovation provision of ADUFA (Animal Drug User Fee Act) for FY 2015.
GeneQuine Biotherapeutics to Present at BioTrinity Conference (May 11-13, 2015, London) [ 04 May 2015 ]
GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at BioTrinity 2015, Europe’s leading Biopartnering and Investment Conference, on May 13, 2015 in London.
Michele Sirghita Starts at GeneQuine as Communications Officer [ 01 Mar 2015 ]
Michele Sirghita, BA, has several years of working experience in the field of project management and corporate communications at international consulting and real estate companies.
A patent for GeneQuine’s lead products was granted by the European Patent Office, which represents a major milestone in securing intellectual protection in the target markets.
Biocentury Publishes Article on GeneQuine [ 22 Dec 2014 ]
GeneQuine was featured as an Emerging Company in the Biocentury journal, the leading provider of biopharma business news, analysis and opinion.
GeneQuine Biotherapeutics to Present at Gene Therapy Conference 2014 (December 3-4, 2014, Brussels) [ 01 Dec 2014 ]
GeneQuine Biotherapeutics, developing gene therapy for joint diseases, will present at Gene Therapy Conference, Europe’s only industry-focused gene therapy Event, on December 4th.
Falling Walls Venture Cup [ 08 Nov 2014 ]
GeneQuine Biotherapeutics became second in the Science Startup of the Year competition at the prestigious Falling Walls conference in Berlin.
Data of the proof-of-concept study with GeneQuine’s lead candidate GQ-201 were featured in two presentations in May 2014 at the leading gene therapy congress ‘American Society of Gene and Cell Therapy Annual Meeting’.
New Website launched [ 22 Feb 2014 ]
Genequine launches new Website.
Dr. André Habel starts at GeneQuine as Head of Manufacturing [ 14 Oct 2013 ]
The seasoned expert in GMP manufacturing of viral agents, Dr. André Habel, is GeneQuine's newest addition to the management team.
GQ-201 as minor use or minor species product classified [ 10 Oct 2013 ]
GeneQuine received a positive decision by EMA's Committee for Medicinal Products for Veterinary Use (CVMP) on classification of GeneQuine's lead candidate GQ-201 as product for minor use or minor species (MUMS).
GeneQuine classified as SME [ 28 May 2013 ]
The European Medicines Agency (EMA) classified GeneQuine as SME (micro, small and medium-sized enterprise).
GeneQuine Biotherapeutics closes Seed Financing [ 12 Nov 2012 ]
The Hamburg, Germany-based biotech startup GeneQuine Biotherapeutics today announced the completion of a seven-figure seed financing round. Investors are the German seed funds High-Tech Gründerfonds, Bonn and Innovationsstarter Fonds Hamburg. Funding will be used to perform proof-of-concept studies with the lead product - a gene therapy drug for the treatment of osteoarthritis in horses.
GeneQuine starts operations in Hamburg, Germany [ 01 Oct 2012 ]
GeneQuine Biotherapeutics, a privately-held biotech startup company, has started operations in October 2012 in Hamburg, Germany.
GeneQuine is "Best of Biotech" [ 10 May 2012 ]
GeneQuine's business case selected as one of the 3 most innovative business ideas at the international business plan competition "Best of Biotech".